tirzepatide trial results once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, retatrutide weight loss trial results

Ozempic: everything you need to know about the weight-loss drug Ozempic has become one of the most known weight-loss drugs, and recent studies suggest that it could do much more Semaglutide, better known for its brand name Ozempic, was developed in 2012 by a team of researchers at the pharmaceutical company Novo Nordisk

Lifestyle changes, aging, and comorbid conditions can alter gastrointestinal responses over time

Tirzepatide has two non-coded amino acid residues at positions 2 and 13 (Aib, -aminoisobutyric acid), and is acylated on K20 P (P indicates that the residue belongs to the peptide) with a Glu-2OEG linker and C18 fatty diacid moiety

Large database analyses from 2023 through 2025 have shown that patients on semaglutide and tirzepatide have lower incident rates of depression, anxiety, and suicidal ideation compared to matched controls on other diabetes medications